Literature DB >> 31041024

Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma.

Pranab M Barman1, Grace L Su2.   

Abstract

Entities:  

Year:  2016        PMID： 31041024      PMCID： PMC6490251          DOI： 10.1002/cld.530

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  4 in total

Review 1.  Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice.

Authors:  Nathan X Chai; Julius Chapiro
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

2.  Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature.

Authors:  Michele Campigotto; Mauro Giuffrè; Anna Colombo; Alessia Visintin; Alessandro Aversano; Martina Budel; Flora Masutti; Cristiana Abazia; Lory Saveria Crocé
Journal:  World J Hepatol       Date:  2020-12-27

Review 3.  Scoring systems for the management of oncological hepato-pancreato-biliary patients.

Authors:  Alexander W Coombs; Chloe Jordan; Sabba A Hussain; Omar Ghandour
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

4.  Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma.

Authors:  Xin Hui Chew; Rehena Sultana; Eshani N Mathew; David Chee Eng Ng; Richard H G Lo; Han Chong Toh; David Tai; Su Pin Choo; Brian Kim Poh Goh; Sean Xuexian Yan; Kelvin Siu Hoong Loke; Sue Ping Thang; Apoorva Gogna; Nanda Karaddi Venkatanarasimha; Aaron K T Tong; Fiona N N Moe; Jacelyn S S Chua; Reiko W T Ang; Aldwin D Ong; Ashley W Y Ng; Marjorie T Q Hoang; Chow Wei Too; Choon Hua Thng; Wan Ying Chan; Wanyi Kee; Jaclyn H M Chan; Farah Irani; Sum Leong; Kiat Hon Lim; Michael L C Wang; Pierce K H Chow
Journal:  Liver Cancer       Date:  2021-04-07       Impact factor: 11.740
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.